Efficacy and Tolerability of Lacosamide in the Treatment of Children With Refractory Generalized Epilepsy
| Autor: | Daphne M Hasbani, Ignacio Valencia, Agustin Legido, Chandrabhaga Miskin, Divya S. Khurana, Karen S. Carvalho |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Male
medicine.medical_specialty Pediatrics Drug Resistant Epilepsy Lacosamide Adolescent Group ii 03 medical and health sciences Epilepsy Young Adult 0302 clinical medicine Refractory Seizures 030225 pediatrics Acetamides medicine Humans In patient Generalized epilepsy Psychiatry Child Retrospective Studies business.industry medicine.disease Treatment Outcome Tolerability Child Preschool Pediatrics Perinatology and Child Health Anticonvulsants Epilepsy Generalized Female Neurology (clinical) business 030217 neurology & neurosurgery Lennox–Gastaut syndrome medicine.drug |
| Zdroj: | Journal of child neurology. 31(7) |
| ISSN: | 1708-8283 |
| Popis: | Lacosamide is FDA-approved in patients 17 years or older with partial-onset epilepsy. We evaluated the efficacy and tolerability of lacosamide in children with refractory generalized epilepsy. We retrospectively reviewed records of 21 children with refractory generalized epilepsy treated with lacosamide in our institution from 2009–2013 divided into 2 subgroups- I, Lennox-Gastaut Syndrome, and II, other generalized epilepsies. Efficacy was defined as seizure freedom or ≥50% seizure reduction. Descriptive data analysis including seizure freedom was compared using c2 analysis. There were eleven females and ten males with a mean age, of 11.9 years. Five patients became seizure free, nine had ≥50% seizure reduction, and seven had no response. Group I: seven had ≥50% improvement, one did not respond. Group II: five became seizure free, two had ≥50% improvement, five had no response. Lacosamide is effective and well tolerated in children with refractory generalized epilepsy particularly patients with Lennox-Gastaut Syndrome. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|